Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0961203315617842 http://scihub22266oqcxt.onion/10.1177/0961203315617842 C4767584!4767584!26637290     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lupus 2016 ; 25 (3): 296-300 Nephropedia Template TP {{tp|p=26637290|t=2016. GlycA, a Novel Marker of Inflammation, is Elevated in Systemic Lupus Erythematosus |pdf=|usr=}}{{26637290}} gab.com Text GlycA, a Novel Marker of Inflammation, is Elevated in Systemic Lupus Erythematosus JO: Lupus http://www.kidney.de/pget.php?&tw=1&pmid=26637290 #FOAvip Background: GlycA is a novel marker of systemic inflammation detected by nuclear magnetic resonance spectroscopy (NMR). In the general population, GlycA is correlated with inflammatory markers such as C-reactive protein (CRP) and associated with coronary heart disease and diabetes. The utility of GlycA in patients with systemic lupus erythematosus (SLE) has not been defined. Therefore, we tested the hypothesis that GlycA concentrations are elevated in patients with SLE and associated with other markers of inflammation and coronary atherosclerosis. Methods: We compared concentrations of GlycA, detected by NMR, in 116 patients with SLE and 84 control subjects frequency-matched for age, sex, and race. SLE disease activity index (SLEDAI) and the SLE Collaborating Clinics damage index (SLICC) were calculated. Acute phase reactants, a panel of cytokines, and a lipid panel were measured. Electron beam computer tomography (EBCT) was used to quantify coronary artery calcification, a measure of coronary artery atherosclerosis. Results: Patients with SLE had higher concentrations of GlycA [398 (350?445)] than control subjects [339 (299?391)] µmol/L, p<0.001. In patients with SLE, concentrations of GlycA were significantly associated with sedimentation rate (rho=0.43), C-reactive protein (rho=0.59), e-selectin (rho=0.28), intracellular adhesion molecule-1 (rho=0.30), triglycerides (rho=0.45), all p<0.0023 to account for multiple comparisons, but not with creatinine, SLEDAI, SLICC, or coronary calcium scores. Conclusions: Concentrations of GlycA are higher in patients with SLE than control subjects and associated with markers of inflammation but not with SLE disease activity or chronicity scores or coronary artery calcification. Twit Text FOAVip GlycA, a Novel Marker of Inflammation, is Elevated in Systemic Lupus Erythematosus ????Lupus http://www.kidney.de/pget.php?&tw=1&pmid=26637290 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26637290 #FOAvip English Wikipedia <ref>{{Cite pmid|26637290}}</ref> GlycA, a Novel Marker of Inflammation, is Elevated in Systemic Lupus Erythematosus #MMPMID26637290 Chung CP; Ormseth MJ; Connelly MA; Oeser A; Solus JF; Otvos JD; Raggi P; Stein CM Lupus 2016[Mar]; 25 (3): 296-300 PMID26637290show ga Background: GlycA is a novel marker of systemic inflammation detected by nuclear magnetic resonance spectroscopy (NMR). In the general population, GlycA is correlated with inflammatory markers such as C-reactive protein (CRP) and associated with coronary heart disease and diabetes. The utility of GlycA in patients with systemic lupus erythematosus (SLE) has not been defined. Therefore, we tested the hypothesis that GlycA concentrations are elevated in patients with SLE and associated with other markers of inflammation and coronary atherosclerosis. Methods: We compared concentrations of GlycA, detected by NMR, in 116 patients with SLE and 84 control subjects frequency-matched for age, sex, and race. SLE disease activity index (SLEDAI) and the SLE Collaborating Clinics damage index (SLICC) were calculated. Acute phase reactants, a panel of cytokines, and a lipid panel were measured. Electron beam computer tomography (EBCT) was used to quantify coronary artery calcification, a measure of coronary artery atherosclerosis. Results: Patients with SLE had higher concentrations of GlycA [398 (350?445)] than control subjects [339 (299?391)] µmol/L, p<0.001. In patients with SLE, concentrations of GlycA were significantly associated with sedimentation rate (rho=0.43), C-reactive protein (rho=0.59), e-selectin (rho=0.28), intracellular adhesion molecule-1 (rho=0.30), triglycerides (rho=0.45), all p<0.0023 to account for multiple comparisons, but not with creatinine, SLEDAI, SLICC, or coronary calcium scores. Conclusions: Concentrations of GlycA are higher in patients with SLE than control subjects and associated with markers of inflammation but not with SLE disease activity or chronicity scores or coronary artery calcification. äGlycA, a Novel Marker of Inflammation, is Elevated in Systemic Lupus E(epmc).pdf DeepDyve Pubget Overpricing